Gunderson Dettmer Advises Tarsus Pharmaceuticals, Inc. on Initial Public Offering

October 15, 2020Client News

Gunderson Dettmer advised client Tarsus Pharmaceuticals, Inc. on its initial public offering of 6,325,000 shares at the price to the public of $16.00 per share for a total of $101 million in aggregate gross proceeds. Tarsus’ common stock is trading on The Nasdaq Global Select Market under the symbol “TARS.”

BofA Securities, Jefferies and Raymond James acted as joint book-running managers for the offering and LifeSci Capital and Ladenburg Thalmann acted as co-managers for the offering.

The Gunderson deal team included partners Ilan Lovinsky, Jeff Vetter, Kirt Shuldberg and Brendan McCarthy, executive compensation counsel Heather Aune and associates Ryan Gunderson, Leanne Gould, Jordan Murray and Brittany Nicely.